Financial Reports, Partnerships, Settlement Agreements, and Strategic Acquisitions - Research Report on Mallinckrodt, WellCare,

    Financial Reports, Partnerships, Settlement Agreements, and Strategic
  Acquisitions - Research Report on Mallinckrodt, WellCare, Mindray, Oxygen
                         Biotherapeutics, and Novavax

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Mallinckrodt plc (NYSE: MNK), WellCare Health Plans, Inc. (NYSE: WCG), Mindray
Medical International Limited (NYSE: MR), Oxygen Biotherapeutics, Inc.
(NASDAQ: OXBT), and Novavax, Inc. (NASDAQ: NVAX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Mallinckrodt plc Research Report

On November 7, 2013, Mallinckrodt plc (Mallinckrodt) released its Q4 FY 2013
and full-year FY 2013 results (period ended September 27, 2013). Mallinckrodt
registered net sales of $552.2 million, up 7.6% YoY in Q4 FY 2013, and net
sales of $2.2 billion, also up 7.6% YoY in full-year FY 2013. The Company
posted net income of $35.8 million, or $0.62 per share in Q4 FY 2013, compared
with 26.2 million, or $0.45 per share in Q4 FY 2012. For full year FY 2013,
net income came in at $61.1 million or $1.06 per share, down from $134.6
million or $2.33 per share in full-year FY 2012. Commenting on the results,
Mark Trudeau, President and CEO of Mallinckrodt, said, "Our Specialty
Pharmaceuticals segment posted strong increases in net sales and operating
income, benefiting from higher-margin products in our Brands and Generics
portfolios. Looking forward, we are optimistic that successful development of
our pipeline will result in launching important new drugs in the market,
further driving Specialty Pharmaceuticals segment growth over the long term.
We are also fully committed to increasing profitability through company-wide
operating efficiencies and growth plans that include targeted international
markets." The Full Research Report on Mallinckrodt plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/24f6_MNK

--

WellCare Health Plans, Inc. Research Report

On November 14, 2013, WellCare Health Plans, Inc. (WellCare) reported that the
Company supported the American Diabetes Association's Step Out: Walk to Stop
Diabetes event in Atlanta on November 9, 2013, to raise awareness and funds to
help the nearly 26 million people across the country that are living with the
disease. Rená B. Cozart, Executive Director, American Diabetes Association,
commented, "The American Diabetes Association, Atlanta/North Georgia Region,
is grateful to WellCare for raising awareness through its participation in
Atlanta's Step Out: Walk to Stop Diabetes and its sponsorship of Team Red."
The Full Research Report on WellCare Health Plans, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/be48_WCG

--

Mindray Medical International Limited Research Report

On November 12, 2013, Mindray Medical International Limited (Mindray)
announced a settlement agreement with Beckman Coulter Inc. Mindray reported
that Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a subsidiary of
Mindray, entered into a settlement agreement related to an ordinary course
commercial dispute with an OEM manufacturing customer, Beckman Coulter Inc. on
November 11, 2013. The Company informed that in connection with this
settlement, it will take a litigation related charge of approximately $15
million in Q4 2013. According to the Company, the commercial dispute did not
involve intellectual property or product liability matters, and Mindray has
determined that the related termination of the OEM arrangement is not material
to its business or operations. The Full Research Report on Mindray Medical
International Limited - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8d4d_MR

--

Oxygen Biotherapeutics, Inc. Research Report

On November 14, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics)
announced that it has closed the acquisition of certain assets of Phyxius
Pharma, a privately-held biopharmaceutical company focused on the development
and near-term commercialization of levosimendan. Pursuant to the purchase
agreement, Oxygen Biotherapeutics reported that it has acquired the exclusive
rights to develop and commercialize levosimendan in North America, and will
welcome three key Phyxius Pharma executives into its management team. The Full
Research Report on Oxygen Biotherapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5700_OXBT

--

Novavax, Inc. Research Report

On November 12, 2013, Novavax, Inc. (Novavax) released its Q3 2013 results.
Novavax registered total revenues of $4.8 million in Q3 2013, down 16.7% YoY.
The Company posted net loss of $15.3 million in Q3 2013, compared to net loss
of $7.2 million in Q3 2012. Also, Novavax reported diluted loss per share of
$0.09 in Q3 2013, compared to diluted loss per share of $0.05 in Q3 2012. The
Full Research Report on Novavax, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/bc35_NVAX

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.